{"id":24483,"date":"2021-03-03T08:17:34","date_gmt":"2021-03-03T06:17:34","guid":{"rendered":"https:\/\/aluksne.lv\/?p=24483"},"modified":"2021-03-03T08:22:17","modified_gmt":"2021-03-03T06:22:17","slug":"neuzkeries-mitiem-par-vakcinam-pret-covid-19-zalu-valsts-agentura-sniedz-uz-pieradijumiem-balstitu-informaciju","status":"publish","type":"post","link":"https:\/\/aluksne.lv\/index.php\/2021\/03\/03\/neuzkeries-mitiem-par-vakcinam-pret-covid-19-zalu-valsts-agentura-sniedz-uz-pieradijumiem-balstitu-informaciju\/","title":{"rendered":"Neuz\u0137eries m\u012btiem par vakc\u012bn\u0101m pret Covid-19!"},"content":{"rendered":"

L\u012bdz \u0161im Latvij\u0101 re\u0123istr\u0113tas tr\u012bs vakc\u012bnas pret Covid-19, bet vair\u0101k k\u0101 200 vakc\u012bnas v\u0113l ir izstr\u0101des stadij\u0101. K\u0101 iesp\u0113jams, ka nepilna gada laik\u0101 izstr\u0101d\u0101t\u0101s vakc\u012bnas ir pietiekami dro\u0161as un efekt\u012bvas lieto\u0161anai? Z\u0101\u013cu valsts a\u0123ent\u016bra (ZVA) sniedz uz zin\u0101tniskiem pier\u0101d\u012bjumiem balst\u012btu inform\u0101ciju, lai klied\u0113tu izplat\u012bt\u0101kos 12 m\u012btus par re\u0123istr\u0113to vakc\u012bnu pret Covid-19 dro\u0161umu, sast\u0101vu un iedarb\u012bgumu.<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

#1 Gada laik\u0101 nevar izstr\u0101d\u0101t vakc\u012bnu<\/strong><\/p>\n

Lai gan izklaus\u0101s neticami, m\u016bsdien\u0101s, pateicoties zin\u0101tnei, vakc\u012bnu izstr\u0101des augstajai att\u012bst\u012bbai, tehnolo\u0123iju risin\u0101jumiem un sadarb\u012bbas operativit\u0101tei starp zin\u0101tniekiem, ra\u017eot\u0101jiem un re\u0123istr\u0113\u0161anas iest\u0101d\u0113m, tas ir noticis! K\u0101? P\u0113tnieki jau vair\u0101k nek\u0101 10 gadus ir p\u0113t\u012bju\u0161i SARS un MERS v\u012brusus un str\u0101d\u0101ju\u0161i pie vakc\u012bn\u0101m pret \u0161iem v\u012brusiem, kas ir pamat\u0101 ar\u012b vakc\u012bnu pret Covid-19 \u0101tr\u0101kai izstr\u0101dei. Turkl\u0101t \u0161o vakc\u012bnu izstr\u0101d\u0113 ieguld\u012bti un apvienoti v\u0113sturiski nebiju\u0161i zin\u0101tnes, finan\u0161u un cilv\u0113kresursi. Gan vakc\u012bnu izstr\u0101des, gan izv\u0113rt\u0113\u0161anas proces\u0101 tika piesaist\u012bts milz\u012bgs ekspertu un zin\u0101tnieku skaits, kas veiku\u0161i kvalitat\u012bvu vakc\u012bnu p\u0101rbaudi atbilsto\u0161i nemain\u012bgi stingr\u0101m re\u0123istr\u0113\u0161anas pras\u012bb\u0101m.<\/p>\n

\u00a0<\/strong><\/p>\n

#2 Vakc\u012bnas nav dro\u0161as un izraisa dz\u012bv\u012bbai b\u012bstamas blakuspar\u0101d\u012bbas<\/strong><\/p>\n

Nav t\u0101du z\u0101\u013cu vai vakc\u012bnu, kur\u0101m neb\u016btu blakuspar\u0101d\u012bbu. Jebkuras z\u0101les tiek apstiprin\u0101tas jeb re\u0123istr\u0113tas tikai tad, ja tiek sa\u0146emti uzticami dati, ka to ieguvums p\u0101rsniedz riskus. Ar\u012b vakc\u012bnas tiek apstiprin\u0101tas tikai gad\u012bjum\u0101, ja to ieguvumi daudzk\u0101rt p\u0101rsniedz riskus. T\u0101pat k\u0101 visas z\u0101les, ar\u012b vakc\u012bnas pret Covid-19 ir r\u016bp\u012bgi p\u0101rbaud\u012btas, iev\u0113rojot augstas pras\u012bbas dro\u0161umam, kvalit\u0101tei un iedarb\u012bgumam. Nek\u0101das atk\u0101pes no stingraj\u0101m pras\u012bb\u0101m ne izstr\u0101dei, ne re\u0123istr\u0113\u0161anai nav veiktas.<\/p>\n

Tie\u0161i t\u0101pat k\u0101 no jebkur\u0101m cit\u0101m z\u0101l\u0113m, ar\u012b p\u0113c vakc\u012bnu pret Covid-19 sa\u0146em\u0161anas atsevi\u0161\u0137os gad\u012bjumos var nov\u0113rot \u012bslaic\u012bgas organisma reakcijas, jo veidojas imunit\u0101tes procesi organism\u0101. Piem\u0113ram, visbie\u017e\u0101k rodas paaugstin\u0101ta temperat\u016bra, drudzis, galvass\u0101pes, nogurums, s\u0101pes vai aps\u0101rtumu injekcijas viet\u0101.<\/p>\n

Pfizer-BioTech un Moderna vakc\u012bnai t\u0101s m\u0113dz b\u016bt izteikt\u0101kas p\u0113c vakc\u012bnas otr\u0101s devas. Savuk\u0101rt AstraZeneca vakc\u012bnai – p\u0113c pirm\u0101s devas. Vis\u0101m vakc\u012bn\u0101m \u0161\u012bs reakcijas visbie\u017e\u0101k rodas pirmaj\u0101s dien\u0101s p\u0113c vakcin\u0101cijas, ilgst da\u017eas dienas un tad izz\u016bd.<\/p>\n

Gad\u012bjum\u0101, ja\u00a0 p\u0113c vakc\u012bnas pret Covid-19 sa\u0146em\u0161anas rodas jebk\u0101das ba\u017eas par nov\u0113rotaj\u0101m blakuspar\u0101d\u012bb\u0101m vai \u012bslaic\u012bgi pazemin\u0101s darbasp\u0113jas, par to j\u0101zi\u0146o \u0101rstam. Gan \u0101rsts vai farmaceits, gan pacients var zi\u0146ot par konstat\u0113t\u0101m z\u0101\u013cu, to vid\u016b ar\u012b vakc\u012bnu, izrais\u012bt\u0101m blakuspar\u0101d\u012bb\u0101m Z\u0101\u013cu valsts a\u0123ent\u016brai t\u012bmek\u013cvietn\u0113 www.zva.gov.lv\u00a0 > \u201cZi\u0146ot par z\u0101\u013cu blakn\u0113m, negad\u012bjumiem ar ier\u012bc\u0113m un biovigilanci<\/a>\u201d.<\/p>\n

Svar\u012bgi, ka vakc\u012bn\u0101m r\u016bp\u012bgi tiks sekots l\u012bdzi ar\u012b turpm\u0101k. Saska\u0146\u0101 ar Covid-19 vakc\u012bnu dro\u0161uma uzraudz\u012bbas pl\u0101nu, ZVA\u00a0 un citas ES z\u0101\u013cu a\u0123ent\u016bras visu laiku apkopo un v\u0113rt\u0113 jaun\u0101ko inform\u0101ciju par vakc\u012bn\u0101m pret Covid-19, k\u0101 ar\u012b cit\u0101m z\u0101l\u0113m, lai nodro\u0161in\u0101tu\u00a0 vakc\u012bnu un z\u0101\u013cu dro\u0161umu un aizsarg\u0101tu sabiedr\u012bbas vesel\u012bbu.<\/p>\n

\u00a0<\/strong><\/p>\n

#3<\/strong> Vakc\u012bn\u0101m nav veikti kl\u012bniskie p\u0113t\u012bjumi ar cilv\u0113kiem (tre\u0161aj\u0101 f\u0101z\u0113)<\/strong><\/p>\n

Vakc\u012bnu vai z\u0101\u013cu re\u0123istr\u0101cija nav iesp\u0113jama bez tre\u0161\u0101s f\u0101zes kl\u012bnisko p\u0113t\u012bjumu ar cilv\u0113kiem rezult\u0101tu snieg\u0161anas un izv\u0113rt\u0113\u0161anas Eiropas Z\u0101\u013cu a\u0123ent\u016br\u0101, jo t\u0101 ir viena no pamatpras\u012bb\u0101m re\u0123istr\u0101cijai. Re\u0123istr\u0113taj\u0101m vakc\u012bn\u0101m pret Covid-19 ir veikti \u0161\u012bs f\u0101zes p\u0113t\u012bjumi un ir izv\u0113rt\u0113ti un Eiropas Z\u0101\u013cu a\u0123ent\u016br\u0101 apstiprin\u0101ti to rezult\u0101ti.<\/p>\n

Veiktos kl\u012bniskos p\u0113t\u012bjumos piedal\u012bj\u0101s vair\u0101ki desmiti t\u016bksto\u0161i cilv\u0113ku. Kl\u012bniskos p\u0113t\u012bjumos ar Pfizer-BionTech izstr\u0101d\u0101to vakc\u012bnu \u201cComirnaty\u201d kopum\u0101 piedal\u012bj\u0101s aptuveni 44 000 cilv\u0113ku. Savuk\u0101rt \u201cModerna\u201d vakc\u012bnas kl\u012bniskos p\u0113t\u012bjumos piedal\u012bj\u0101s aptuveni 30 000 cilv\u0113ku. Kl\u012bniskos p\u0113t\u012bjumos ar \u201cAstraZeneca\u201d vakc\u012bnu piedal\u012bj\u0101s aptuveni 24 000 cilv\u0113ku.<\/p>\n

\u00a0<\/strong><\/p>\n

#4 Viena uz\u0146\u0113muma vakc\u012bna ir lab\u0101ka nek\u0101 otra uz\u0146\u0113muma vakc\u012bna<\/strong><\/p>\n

Visas Latvij\u0101 re\u0123istr\u0113t\u0101s vakc\u012bnas ir ar augstu iedarb\u012bbu Covid-19 smagas saslim\u0161anas nov\u0113r\u0161an\u0101. Neviena no \u0161obr\u012bd apstiprin\u0101taj\u0101m vakc\u012bn\u0101m nav uzskat\u0101ma par lab\u0101ku vai slikt\u0101ku. Visas re\u0123istr\u0113t\u0101s vakc\u012bnas ir vien\u0101di p\u0101rbaud\u012btas, kvalitat\u012bvas, iedarb\u012bgas un dro\u0161as. Vakc\u012bnas tiek re\u0123istr\u0113tas tikai gad\u012bjum\u0101, kad Eiropas Z\u0101\u013cu a\u0123ent\u016bra sa\u0146em pier\u0101d\u012bjumus, ka vakc\u012bnu ieguvums daudzk\u0101rt p\u0101rsniedz riskus. Turkl\u0101t, lai vakc\u012bnas pilnv\u0113rt\u012bgi savstarp\u0113ji sal\u012bdzin\u0101tu, ir j\u0101veic \u0161\u0101ds sal\u012bdzino\u0161s p\u0113t\u012bjums.<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/strong><\/p>\n

#5 Vakc\u012bnas nepasarg\u0101 no jaunajiem Covid-19 v\u012brusa veidiem<\/strong><\/p>\n

Ir p\u0101rbaud\u012bts, ka l\u012bdz \u0161im re\u0123istr\u0113t\u0101s vakc\u012bnas pret Covid-19 aizsarg\u0101 pret jaunajiem v\u012brusa paveidiem. Ta\u010du, \u0146emot v\u0113r\u0101, ka da\u017ei jauno v\u012brusa veidi tom\u0113r var ietekm\u0113t vakc\u012bnu sp\u0113ju aizsarg\u0101t pret infekciju un slim\u012bbu att\u012bst\u012bbu, Eiropas Z\u0101\u013cu a\u0123ent\u016bra aicin\u0101jusi vakc\u012bnu ra\u017eot\u0101jus iesniegt papildu pier\u0101d\u012bjumus vakc\u012bnu iedarb\u012bbai.<\/p>\n

\u00a0<\/strong><\/p>\n

#6 Nav zin\u0101ms, cik ilgi vakc\u012bna pasarg\u0101 pret Covid-19<\/strong><\/p>\n

P\u0113t\u012bjumu dati liecina, ka visas l\u012bdz \u0161im apstiprin\u0101t\u0101s vakc\u012bnas nodro\u0161ina ne maz\u0101k k\u0101 2 m\u0113ne\u0161u aizsardz\u012bbu pret Covid-19. Vakc\u012bna pasarg\u0101 no simptom\u0101tiskas saslim\u0161anas, tai skait\u0101 no smagas slim\u012bbas gaitas un no n\u0101ves.<\/p>\n

P\u0113t\u012bjumi par nodro\u0161in\u0101t\u0101s aizsardz\u012bbas ilgumu v\u0113l joproj\u0101m turpin\u0101s, un vakc\u012bnu izstr\u0101d\u0101t\u0101ji veic ar\u012b vakc\u012bnu sa\u0146\u0113mu\u0161o dal\u012bbnieku nov\u0113r\u0161anu ilgtermi\u0146a efektivit\u0101tes p\u0113t\u012bjumos, lai noskaidrotu prec\u012bzu vakc\u012bnas aizsardz\u012bbas ilgumu.<\/p>\n

\u00a0<\/strong><\/p>\n

#7 Vakc\u012bnas neaizsarg\u0101s, jo nevienai no t\u0101m nav apstiprin\u0101ta 100 % efektivit\u0101te<\/strong><\/p>\n

Vakc\u012bnas atvieglo un nov\u0113r\u0161 smagu saslim\u0161anas gaitu, ierosinot im\u016bnsist\u0113mas aizsargreakciju p\u0113c saskar\u0161an\u0101s ar v\u012brusu. Vakc\u012bnas p\u0113t\u012bjumos ir demonstr\u0113ju\u0161as efektivit\u0101ti pasarg\u0101t cilv\u0113kus no simptom\u0101tiskas saslim\u0161anas. Tas ietver ar\u012b smagu slim\u012bbas gaitu.<\/p>\n

Pirms vakc\u012bnas apstiprin\u0101\u0161anas tika veikti\u00a0 p\u0113t\u012bjumi, kuros iesaist\u012btos cilv\u0113kus sadal\u012bja div\u0101s grup\u0101s. Viena grupa sa\u0146\u0113ma vakc\u012bnu, bet otra – ne\u012bstu vakc\u012bnu. Ab\u0101s grup\u0101s tika v\u0113rt\u0113ts saslimu\u0161o skaits p\u0113c \u012bstas vai ne\u012bstas vakc\u012bnas sa\u0146em\u0161anas un, balstoties uz rezult\u0101tu, apr\u0113\u0137in\u0101ts vakc\u012bnas efektivit\u0101tes r\u0101d\u012bt\u0101js.\u00a0 Atsevi\u0161\u0137u vakc\u012bnu p\u0113t\u012bjumi turpin\u0101s ar\u012b \u0161obr\u012bd, lai ieg\u016btu papildu ilgtermi\u0146a datus, cik labi un ilgi t\u0101s aizsarg\u0101.<\/p>\n

\u00a0<\/strong><\/p>\n

#8\u00a0 Vakc\u012bna nedarbojas cilv\u0113kiem no 65 gadu vecuma<\/strong><\/p>\n

Pasaules Vesel\u012bbas organiz\u0101cija, Eiropas Z\u0101\u013cu a\u0123ent\u016bra un Latvijas Imuniz\u0101cijas valsts padome, izv\u0113rt\u0113jot pieejamos datus apstiprin\u0101jusi, ka \u201cAstraZeneca\u201d izstr\u0101d\u0101t\u0101 vakc\u012bna sniedz aizsardz\u012bbu pret Covid-19 visu vecuma grupu cilv\u0113kiem, s\u0101kot no 18 gadu vecuma, tostarp ar\u012b vec\u0101ka gadag\u0101juma cilv\u0113kiem.\u00a0<\/p>\n

Eiropas Z\u0101\u013cu a\u0123ent\u016bras zin\u0101tniskie eksperti p\u0113c r\u016bp\u012bgas vakc\u012bnas \u201cCovid-19 Vaccine AstraZeneca\u201d izv\u0113rt\u0113\u0161anas un sniedzot ieteikumu Eirop\u0101 re\u0123istr\u0113t \u0161o vakc\u012bnu, ir nor\u0101d\u012bju\u0161i, ka AstraZeneca izstr\u0101d\u0101t\u0101 vakc\u012bna pret Covid-19 sniegs aizsardz\u012bbu ar\u012b gados vec\u0101kiem cilv\u0113kiem.<\/p>\n

Balstoties uz pieredzi ar cit\u0101m vakc\u012bn\u0101m un\u00a0 \u0146emot v\u0113r\u0101, ka ar\u012b gados vec\u0101kiem cilv\u0113kiem p\u0113c vakcin\u0101cijas ar AstraZeneca vakc\u012bnu tika nov\u0113rota im\u016bnatbilde, \u0161iem cilv\u0113kiem sagaid\u0101ma vakc\u012bnas rad\u012bta aizsardz\u012bba, lai gan \u0161obr\u012bd v\u0113l nav pieejams pietiekami daudz datu, lai statistiski prec\u012bzi pateiktu, k\u0101du tie\u0161i iedarb\u012bguma jeb iedarb\u012bbas lielumu vakc\u012bna nodro\u0161in\u0101s cilv\u0113kiem vecum\u0101 p\u0113c 65 gadiem.<\/p>\n

Turkl\u0101t ir g\u016bti p\u0101rliecino\u0161i pier\u0101d\u012bjumi par vakc\u012bnas lieto\u0161anas dro\u0161umu \u0161ai vecuma grupai.<\/p>\n

\u00a0<\/strong><\/p>\n

#9 Vakc\u012bnas ir kait\u012bgas sieviet\u0113m, kuras pl\u0101no gr\u016btniec\u012bbu, gaida b\u0113rnu vai baro b\u0113rnu ar kr\u016bti<\/strong><\/p>\n

Zin\u0101tnieki p\u0113c r\u016bp\u012bgas vakc\u012bnu izv\u0113rt\u0113\u0161anas un \u0101rsti apstiprina, ka vakc\u012bnas nekait\u0113 gr\u016btniec\u0113m un sieviet\u0113m, kuras pl\u0101no gr\u016btniec\u012bbu vai baro b\u0113rnu ar kr\u016bti. Vakc\u012bnas nav kait\u012bgas ne pa\u0161\u0101m sieviet\u0113m, ne z\u012bdainim, ne ar\u012b vi\u0146u v\u0113l nedzimu\u0161ajam b\u0113rnam. To apstiprina laboratorij\u0101s veikti l\u012bdz\u0161in\u0113jie p\u0113t\u012bjumi un, \u0146emot v\u0113r\u0101, ka pla\u0161a vakcin\u0101cija turpin\u0101s vis\u0101 pasaul\u0113, kad ir jau vakcin\u0113ti vair\u0101ku miljonu cilv\u0113ku, \u0161obr\u012bd tiek iev\u0101kti ar\u012b dati par ilgtermi\u0146a ietekmi.<\/p>\n

Turkl\u0101t \u0101rsti vakcin\u0113ties \u012bpa\u0161i iesaka sieviet\u0113m, kuras pieder\u00a0 k\u0101dai no riska grup\u0101m, jo vakc\u012bnas ieguvums ir liel\u0101ks nek\u0101 slim\u012bbas rad\u012btais risks. T\u0101 k\u0101 tikai \u0101rsts var izlemt par vakcin\u0113\u0161anos gr\u016btniec\u012bbas laik\u0101, izv\u0113rt\u0113jot ieguvumus un riskus ne vien sievietei, bet ar\u012b b\u0113rnam, pirms vakcin\u0113\u0161an\u0101s oblig\u0101ti j\u0101konsult\u0113jas ar speci\u0101listu.<\/p>\n

\u00a0<\/strong><\/p>\n

#10 Vakc\u012bnas satur embriju \u0161\u016bnas un mikro\u010dipus<\/strong><\/p>\n

Vakc\u012bnas ir veidotas m\u0101ksl\u012bgi laboratorij\u0101s, l\u012bdz ar to nesatur dz\u012bvu v\u012brusu, k\u0101 ar\u012b to izgatavo\u0161an\u0101 nav izmantotas cilv\u0113ku, embriju vai dz\u012bvnieku \u0161\u016bnas vai mikro\u010dipi.<\/p>\n

\u00a0<\/strong><\/p>\n

#11 Vakc\u012bnas ir piem\u0113rotas b\u0113rniem<\/strong><\/p>\n

N\u0113, vakc\u012bnas nav pagaid\u0101m paredz\u0113tas b\u0113rnu l\u012bdz 16 gadu vecumam vakcin\u0113\u0161anai.\u00a0 Uz\u0146\u0113mumu \u201cPfizer\u2013BioNTech\u201d izstr\u0101d\u0101to vakc\u012bnu dr\u012bkst lietot, s\u0101kot no 16 gadu vecuma, bet uz\u0146\u0113muma \u201cModerna\u201d un \u201cAstraZeneca\u201d vakc\u012bnas paredz\u0113tas pieaugu\u0161ajiem, s\u0101kot no 18 gadu vecuma. Ra\u017eot\u0101ji ir s\u0101ku\u0161i veikt kl\u012bniskos p\u0113t\u012bjumus, lai p\u0101rbaud\u012btu vakc\u012bnu pret Covid-19 piem\u0113rot\u012bbu b\u0113rniem.<\/p>\n

\u00a0<\/strong><\/p>\n

#12 Nav pieejama uzticama inform\u0101cija par vakc\u012bn\u0101m <\/strong><\/p>\n

Lai iedz\u012bvot\u0101ji var\u0113tu \u0113rt\u0101k rast uzticamu un zin\u0101tn\u0113 balst\u012btu inform\u0101ciju par vakc\u012bnu pret Covid-19 izstr\u0101di, ZVA t\u012bmek\u013cvietnes www.zva.gov.lv\u00a0<\/a><\/u> sada\u013c\u0101 \u201cCovid-19 zi\u0146as<\/a><\/u>\u201d regul\u0101ri tiek aktualiz\u0113ta un public\u0113ta jaun\u0101k\u0101 inform\u0101cija par vakc\u012bnu izstr\u0101di, v\u0113rt\u0113\u0161anu un apstiprin\u0101\u0161anu, tai skait\u0101 par vakc\u012bnu iedarb\u012bgumu, kvalit\u0101ti un dro\u0161umu\u00a0 un fakti par vakc\u012bn\u0101m.<\/a><\/u><\/p>\n

Inform\u0101cija par vakc\u012bnas sa\u0146em\u0161anas k\u0101rt\u012bbu un vakcin\u0101cijas norisi Latvij\u0101 \u2013 Slim\u012bbu profilakses un kontroles t\u012bmek\u013cvietnes sada\u013c\u0101 \u201cVakc\u012bnas pret Covid-19<\/a><\/u>\u201d. Lai iedz\u012bvot\u0101ji var\u0113tu pieteikties vakc\u012bnas pret Covid-19 sa\u0146em\u0161anai, Latvij\u0101 ir izveidota Covid-19 vakc\u012bnas pieteik\u0161an\u0101s vietne www.manavakcina.lv. Vakcin\u0113\u0161an\u0101s pret Covid-19 ir br\u012bvpr\u0101t\u012bga un piln\u012bb\u0101 valsts apmaks\u0101ta.<\/p>\n","protected":false},"excerpt":{"rendered":"

L\u012bdz \u0161im Latvij\u0101 re\u0123istr\u0113tas tr\u012bs vakc\u012bnas pret Covid-19, bet vair\u0101k k\u0101 200 vakc\u012bnas v\u0113l ir izstr\u0101des stadij\u0101. K\u0101 iesp\u0113jams, ka nepilna gada laik\u0101 izstr\u0101d\u0101t\u0101s vakc\u012bnas ir pietiekami dro\u0161as un efekt\u012bvas lieto\u0161anai? Z\u0101\u013cu valsts a\u0123ent\u016bra (ZVA) sniedz uz zin\u0101tniskiem pier\u0101d\u012bjumiem balst\u012btu…
Las\u012bt visu<\/a><\/p>\n","protected":false},"author":1,"featured_media":24488,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_crdt_document":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[9],"tags":[],"class_list":["post-24483","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noderiga-informacija"],"_links":{"self":[{"href":"https:\/\/aluksne.lv\/index.php\/wp-json\/wp\/v2\/posts\/24483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aluksne.lv\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aluksne.lv\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aluksne.lv\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/aluksne.lv\/index.php\/wp-json\/wp\/v2\/comments?post=24483"}],"version-history":[{"count":0,"href":"https:\/\/aluksne.lv\/index.php\/wp-json\/wp\/v2\/posts\/24483\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aluksne.lv\/index.php\/wp-json\/wp\/v2\/media\/24488"}],"wp:attachment":[{"href":"https:\/\/aluksne.lv\/index.php\/wp-json\/wp\/v2\/media?parent=24483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aluksne.lv\/index.php\/wp-json\/wp\/v2\/categories?post=24483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aluksne.lv\/index.php\/wp-json\/wp\/v2\/tags?post=24483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}